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ABSTRACT 
Thrombotic diseases rarely cause symptoms until advanced stage and sudden death. 
Thus, early detection of thrombus by a widely spread imaging modality can improve 
the prognosis and reduce mortality. Here, polymer microbubbles (MBs) made of 
degradable poly(IsoButylCyanoAcrylate) and functionalized with fucoidan 
(Fucoidan-MBs) were designed as a new targeted ultrasound contrast agent to image 
venous thrombus. The physicochemical characterizations demonstrate that the MBs 
with fucoidan surface exhibit a size of 2-6 μm and stability in suspension at 4°C up to 
2 months. MBs exhibit high echogenicity and could be completely burst under high 
destructive pulse. Flow chamber experiments on activated human platelets show a 
higher affinity of Fucoidan-MBs than control anionic MBs (CM-Dextran-MBs) under 
shear stress conditions. In vivo analysis by ultrasound and histological results 
demonstrate that Fucoidan-MBs are localized in rat venous thrombotic wall, whereas 
few CM-Dextran-MBs are present. In addition, the binding of Fucoidan-MBs in 
healthy vein is not observed. Collectively, Fucoidan-MBs appear as a promising 
functionalized carrier for ultrasound molecular imaging in thrombotic diseases. 
 
Keywords: polymer microbubbles, fucoidan, P-selectin, molecular ultrasound 
imaging, thrombosis 
  
1. Introduction 
Thrombotic diseases, such as deep vein thrombosis, are often called “the silent killer” 
because they rarely cause symptoms until an advanced stage [1-3]. Early detection 
and treatment can improve the prognosis and reduce mortality. P-selectin, an adhesion 
molecule, mainly expressed on the surface of activated platelets and injured vascular 
endothelium, is involved in the pathophysiology of intraluminal thrombus formation 
and other cardiovascular diseases [4, 5]. These features suggest that P-selectin can be 
an important target for molecular imaging of thrombosis or in acute and chronic 
cardiovascular diseases [6-8]. 
We have previously demonstrated that fucoidan, an abundant and cost-effective 
marine polysaccharide with sulfated chains, exhibits a high affinity for immobilized 
P-selectin in vitro [9, 10]. 
99m
Tc-fucoidan as a radiotracer has already proved in vivo to 
be able to detect thrombus and heart ischemia associated with the P-selectin 
overexpression in our previous studies [11, 12]. Recently, we have developed 
fucoidan functionalized core-shell polymer microcapsules and proved that they have 
high specific binding efficiency to P-selectin under flow conditions [13]. Moreover, 
fucoidan functionalized nano-/microparticles have also been developed as a molecular 
contrast agent to monitor thrombi by Magnetic Resonance Imaging (MRI) or 
Single-Photon Emission Computed Tomography (SPECT) imaging [14-16]. 
Compared to other imaging modalities, ultrasound imaging has numerous advantages, 
including comfortable, noninvasive, portable, low cost real-time imaging, lack of 
ionizing radiation and excellent safety profile [17, 18]. Ultrasound imaging equipment 
is already present in most hospitals all around the world and even in private health 
centers. However, ultrasound image quality is limited by its poor contrast due to the 
low differences in acoustic characteristics of organs in vivo. The development and use 
of microbubbles (MBs) have redeemed this shortage tremendously [19-22]. 
Traditional MBs are mainly made up of albumin/lipid/surfactant shells and have not 
only been applied as ultrasound agents, but also have been used in versatile 
biomedical applications including drugs, genes and drug-loaded nanoparticles targeted 
delivery [23, 24]. Recently, polymeric shells MBs have received increasing attention 
due to their improved stability and some polymersomes have also been applied in 
drug controlled release at the target site under a specific stimulus such as ultrasound 
[25, 26]. Poly(AlkylCyanoAcrylate) with long alkylcyanoacrylate monomers (for 
example, n-butyl, isobutyl, isohexyl and octyl) has been extensively investigated to 
design micro-/nanocarriers since the 80s [27, 28]. The first Poly(ButylCyanoAcrylate) 
microbubbles called Sonavist
®
 were manufactured by one-step process through 
adding the n-butyl-2-cyanoacrylate monomers into gas-water emulsion [29, 30]. 
Palmowski et al. further synthesized streptavidin-coated PBCA microbubbles and 
investigated their physicochemical properties [31-33]. Subsequent studies proved that 
these microbubbles could be functionalized by conjugating with monoclonal 
antibodies that recognize receptor proteins involved in various diseases [34-36]. 
However, employing, for instance, biotin/streptavidin and antibodies limited their use 
in humans because of the costs and potential immunogenicity of streptavidin and 
antibodies. Recently, various bubbles using small peptides instead of antibodies for 
binding without using the biotin-streptavidin coupling strategy have already been 
developed to address these problems [37, 38]. Among them, BR55, as the most 
potential targeted-MBs contrast agent, shows that it could be used to detect the 
prostate cancer or monitor breast and ovarian lesions in human clinical trials [39, 40]. 
In the view of future clinical applications, MBs assembled by clinically approved 
polymers and suitable targeting ligands are interesting for clinical use and market 
requirements.  
In this work, we report a new one-step process to obtain polysaccharide-coated 
poly(IsoButylCyanoAcrylate) (PIBCA) microbubbles. Among them, fucoidan 
functionalized microbubbles (Fucoidan-MBs) were considered as a targeted 
ultrasound molecular imaging probe for P-selectin. Targeting of Fucoidan-MBs was 
evaluated in vitro using flow chambers with activated human platelets. In vivo 
experiments performed in a FeCl3-induced thrombus rat model showed that 
Fucoidan-MBs were located in the thrombotic area but not in healthy rats, which 
confirms the ability of Fucoidan-MBs to specifically target P-selectin. These 
functionalized echogenic microbubbles appear as new tools for imaging at molecular 
level cardiovascular events in which P-selectin is overexpressed. 
  
2. Materials and Methods 
Materials: Dextran 70, anionic CarboxyMethyl-Dextran 40 (CM-Dextran), 
FITC-CarboxyMethyl-Dextran 40 (FITC-CM-Dextran) and cationic 
2-DiEthylAminoethyl-Dextran 70 (DEAE-Dextran) were provided from TdB 
Consultancy (Uppsala, Sweden). Fucoidan (Mn = 18 kDa / Mw = 104 kDa) was 
obtained from Algues & Mer (Ouessant, France). Isobutylcyanoacrylate (IBCA) 
monomers were purchased by ORAPI (Saint Vulbas, France). Methylene blue hydrate 
was purchased from Sigma-Aldrich. Chromatography was obtained from GE 
Healthcare. Mouse anti-human CD62P-FITC and mouse IgG1-FITC Isotype Control 
were provided from Beckman Coulter (Villepinte, France). Fibrillar type I collagen 
Horm
®
 was obtained from Takeda (Linz, Austria). 24-, 96-Well Cell Culture Plates 
(Costar) were obtained from Corning Incorporated. PPACK tubes were purchased 
from Cryopep (Montpellier, France). Flow chambers (Vena8 Fluoro+) were provided 
from Cellix Ltd (Dublin, Ireland). 
Synthesis of Microbubbles: Poly(IsoButylCyanoAcrylate) (PIBCA) shelled 
air-containing microbubbles (MBs) were prepared by modification of established 
emulsion polymerization process as described by Palmowski et al. [33]. Briefly, 700 
µL of IBCA monomer was loaded in a 1 mL plastic syringe, injected into 50 mL of an 
aqueous solution of 1% Tween 20 at pH 2.5 via a catheter at a constant flow rate of 5 
mL h
-1
, and dispersed at 20,000 rpm for 60 min with a homogenizer 
(ULTRA-TURRAX
®
, IKA, Germany). The syringe pump (AL-300, World Precision 
Instruments, Florida, USA) was used to control flow rate. The resulting microbubble 
suspension was then washed three times by centrifugation (500 rpm, 20 min, 5702RH 
centrifuge Beckman Coulter, Villepinte, France) to obtain the monodispersed bubble 
populations and to remove the polymeric scrap. Subsequently, the resulted emulsion 
was placed into a separatory funnel overnight, and the aqueous layer was removed. 
The microbubbles layer was redispersed in 30 mL of 0.02% Tween 20 for storage at 
4°C. To prepare polysaccharide functionalized microbubbles (Dextran-MBs, 
DEAE-Dextran-MBs, CM-Dextran-MBs and Fucoidan-MBs), 500 mg of 
corresponding polysaccharides were dissolved in an aqueous solution before IBCA 
introduction. For Rhodamine B loaded CM-Dextran-MBs and Fucoidan-MBs 
(CM-Dextran-RhoB-MBs and Fucoidan-RhoB-MBs, respectively), 1 mg of 
Rhodamine B was added into an aqueous solution before synthesis. 
FITC-CM-Dextran-MBs and FITC-Fucoidan-MBs were obtained by using 10 mg of 
FITC-CM-Dextran mixed with 490 mg of CM-Dextran and 10 mg of FITC-Fucoidan 
mixed with 490 mg of Fucoidan, respectively. Rhodamine B loaded 
FITC-CM-Dextran-MBs and FITC-Fucoidan-MBs were prepared by combining two 
protocols. 
Microbubbles Size and Zeta Potential Analysis: The size range of microbubbles 
was determined using a Mastersizer 3000 (Malvern Instruments, UK) equipped with a 
Hydro SM sample dispersion unit. A suspension of microbubbles was dispersed into 
0.02% Tween 20 solution and stirred at 1,500 rpm for 1 minute before an examination. 
Zeta potential (ζ) of the microbubbles was measured with samples diluted into 
electrolyte solution (1 × 10
−3
 M KCl & 0.02% Tween 20) using electrophoretic light 
scattering apparatus (Nano ZS, Malvern Instruments, UK) at 25°C. All the 
measurements were performed at least three times. 
Environmental Scanning Electron Microscopy (ESEM) and Scanning Electron 
Microscopy (SEM): The surface morphology of microbubbles was imaged using an 
ESEM apparatus (Philips XL30 ESEM-FEG, Amsterdam, Netherlands) and SEM 
apparatus (JSM-IT100, Jeol, Japan). The interaction of Fucoidan-MBs with activated 
platelets on an ex vivo platelets-rich thrombus was also visualized using ESEM. 
Briefly, to obtain the ex vivo platelets-rich thrombus, the blood was collected in citrate 
tubes and then centrifuged at 120 G for 15min. Plasma rich in platelets (PRP) was 
collected and distributed in small glass tubes (370 µL). To activate platelets, calcium 
chloride was added (7 µL at 1M) and the tubes were incubated at 37 °C for 1h. The 
platelet-rich thrombus was detached from the walls of the glass tubes and then 
transferred to a 96-well plate where it was be put in contact with Fucoidan-MBs for 5 
min. After several rinses with 0.9% NaCl, the thrombus was fixed at 4% 
paraformaldehyde for 24 hours and then rinsed for visualization by ESEM. 
The binding of Fucoidan-MBs on the luminal thrombus of inferior vena cava was 
observed using ESEM. Briefly, we performed an inferior vena cava thrombus rat 
model induced by ferric chloride (FeCl3), and injected Fucoidan-MBs. The rat was 
then euthanatized and the inferior vena cava with thrombus was picked up and fixed 
in 4% paraformaldehyde for 24 hours and rinsed in saline. The inferior vena cava was 
opened longitudinally on the top to observe the thrombus by ESEM. 
Confocal imaging: Microbubbles were imaged using Zeiss LSM 780 confocal 
microscope fitted with 63X objective. Microbubbles were detected using rhodamine B 
and polysaccharides with FITC-Fucoidan and FITC-CM-Dextran. 
Quantification of Fucoidan content: The amount of fucoidan in microbubbles 
was determined by methylene blue staining of sulfated polysaccharides [41]. Several 
1×1 cm square chromatography paper were placed in 24-well plate. The solution was 
cautiously added dropwise at the center of these squares, 2 μL for each drop; the next 
portions were dropped on the same point after drying off the last drop in the oven 
(Jouan, France) for 10 min at 50°C. The filter papers with loaded sample drops were 
kept in the oven overnight at 50°C, dried thoroughly and then treated with a mixture 
of methanol and acetone (6:4) for 3 min. Fucoidan spots on filter paper were 
visualized after 10 min at room temperature in staining solution containing 50 mM 
HCl and 0.1% (w/w) methylene blue in a mixture of methanol/acetone/water (6:4:15). 
The filter paper was washed several times with a mixture of acetic 
acid/methanol/acetone/water (5:6:4:75) to remove the excess of methylene blue. 
Images were taken, and filter paper squares were put into 1.5 ml Eppendorf centrifuge 
tubes with 0.5 ml of methanol containing 2% SDS during 15 min at 50°C. A volume 
of 0.1 ml of this extract was transferred into 96-well plate, and absorbance was 
determined at 663 nm by infinite
®
 200 PRO (TECAN, Switzerland). The series of 
filter paper squares containing stained standard solution spots was obtained by adding 
5 drops (10 μL) of different concentration of fucoidan or CM-Dextran solutions (0.5, 
0.25, 0.125, 0.0625 and 0.3125 mg mL
-1
) to each filter paper. The relative absorbance 
(△abs) of fucoidan - methylene blue complex at A663 nm was expressed as [abs 
(fucoidan) - abs (CM-Dextran)]. Fucoidan content was plotted against the △abs for 
the regression line. For MBs samples, 3 × 10
8
 Fucoidan or CM-Dextran microbubble 
suspension was placed into a separatory funnel overnight, and the aqueous layer was 
removed to eliminate free fucoidan. The clot of microbubbles was totally hydrolysed 
by mixing with alkaline solution (0.1 N NaOH and 0.02% Tween 20) overnight, and 
the resulted solution was added dropwise on filter paper square.  
Flow Chamber Experiments: Platelet dynamic binding experiments were 
performed according to our previous methods [13]. Briefly, Vena8 Fluoro+ channels 
were coated with 50 μg.mL-1 of collagen overnight in a wet chamber at 4°C and 
washed with 0.9% NaCl before use. Collagen fibers covering the channels were 
visualized by phase contrast microscopy. Human whole blood samples (EFS, Hôpital 
Bichat, Paris, France) were collected in 75 μM PPACK tubes and perfused through the 
channels for 5~10 min at arterial shear stress (67.5 dyn.cm
-2
). Platelet activation and 
aggregation through contact with collagen in the channels were visualized in real time 
with phase contrast microscopy (Carl Zeiss Microscopy, Oberkochen, Germany). 
Channels were washed for 1 min with 0.9% NaCl. To confirm P-selectin expression 
on platelets, 20 µg.mL
−1 
of FITC anti-CD62P antibody was infused into one channel 
after platelet aggregation at arterial shear stress for 5 minutes, and the same 
concentration of isotype-matched FITC-IgG was injected through the other channel as 
a control. For binding assay, platelets were labeled with DIOC6 (0.15 × 10
−3
 M) 
before their injection. After platelet aggregation, fluorescent microbubbles 
(CM-Dextran-RhoB-MBs or Fucoidan-RhoB-MBs) were injected through the 
channels at 1 × 10
8
 mL
-1
 for 5 min under venous shear stress (6.75 dyn.cm
-2
). 
Channels were finally washed for 15 min with 0.9% NaCl at the same shear stress. 
Fluorescence microscopy videos and images were taken along each channel using the 
same parameters. Quantitative analysis was performed on 7 channels per type of 
microbubbles. The mean fluorescent intensity of the red fluorescence channel of 
twenty aggregates was measured using Zen 2012 Software (Carl Zeiss, Oberkochen, 
Germany). 
In Vitro Ultrasound Imaging: Ultrasound imaging performances were evaluated 
with a VisualSonics Vevo
®
 2100 imaging system (FUJIFILM VisualSonics Inc., 
Canada) connected to a high-frequency transducer (MS550D, VisualSonics). The 
set-up parameters were: frequency (40 MHz), the acquisition contrast gain (20 dB), 
the transmit power (4%), the frame rate (33) and the dynamic range (35 dB). All the 
parameters were constant throughout all image acquisition. A suspension of MBs (10
5
 
mL
-1
) dispersed into thin-wall PCR tubes was placed on the top of the probe, and the 
images were obtained by B-mode and linear contrast mode. The burst of microbubbles 
was performed by using high mechanical index destructive pulse (duration: 1 second). 
The values of B-mode mean power of 100 frames before and after the destructive 
pulse were calculated by VevoCQ™ advanced contrast quantification software and 
shown within the scatter plot. To analyze quantitatively the contrast enhancement 
effect, the mean values of B-mode power of 100 frames before and after burst were 
calculated. 
In Vitro Cytotoxicity: Mouse fibroblast 3T3 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 
4 mmol of L-glutamine, 1% (v/v) of penicillin and 1% (v/v) of streptomycin. The 
cells were kept in an incubator at 37°C in a humidified atmosphere of 5% CO2, 95% 
air. Cells were seeded (at the density of 10
4
 cells per well) in 96-well plates and 
incubated for 24 h. The cell culture medium was removed, and 200 µL of series of 
dilution (10
7
, 10
6
, 10
5
 and 10
4
 mL
-1
) of microbubbles were added in the medium. 
Culture media were used as a control. After 24 h of incubation, the supernatant was 
removed, 10 µL (5 mg mL
−1
) of MTT solution was added to the medium in each well, 
and the plates were incubated for 4 h at 37°C and 5% CO2. The medium with MTT 
was removed, and 100 µL per well of isopropanol solution was added to each well to 
dissolve the formazan crystals. Absorbance was measured immediately using a 
TECAN (Infinite M200 PRO) at 490 nm. The relative cell viability was expressed as 
(absorbance of microbubbles/absorbance of the control) × 100%. 
In Vivo Model of Thrombosis on Rat Deep Vein: Animal studies were done in 
accordance with principles of laboratory animal care and with the approval of the 
animal care and use committee of the Claude Bernard Institute (N°2012-15/698-0100, 
Paris, France). FeCl3-induced thrombosis model on rat deep vein was induced based 
on the previous work [42]. Briefly, Wistar male rats (Janvier Labs, Le 
Genest-Saint-Isle, France) aged around 7 weeks were anesthetized with an 
intraperitoneal injection of pentobarbital (1 μL g−1 body weight, Ceva Santé Animale 
SA, La Ballastiere, France). A midline abdominal incision was performed to expose 
the inferior vena cava (IVC). Venous thrombus was generated by applying a 2 mm 
Whatman chromatography paper saturated with 10% FeCl3 on top of the IVC in 
contact with the adventitial surface of the vessel for 5 minutes. After the paper was 
removed, the vein was washed several times with a saline solution. Typically, 
thrombus development was completed 30 minutes post FeCl3 injury. Ten 
thrombosis-bearing rats were randomly divided into two groups, one group of rats 
received Fucoidan-MBs intracavernous injection (200 μL, 1 × 108/mL), the other 
group was injected with CM-Dextran-MBs (200 μL, 1 × 108/mL). As the control, 
three healthy rats were also injected with Fucoidan-MBs (200 μL, 1 × 108/mL). All 
rats were kept anesthetized during the entire imaging process.  
In Vivo Ultrasound Molecular Imaging: Ultrasound imaging of venous 
thrombosis (in rat thrombus model) or venous wall (in healthy rats) was performed 
using a VisualSonics Vevo
®
 2100 imaging system with the same parameters used in 
vitro. Briefly, the ultrasound transducer was placed perpendicular and parallel to the 
IVC, 10 minutes after injection of MBs. A cine loop was acquired in the B-mode and 
linear contrast mode which made series of imaging frames before and after a high 
mechanical index destructive pulse (duration: 1 second). Using the Advanced Contrast 
Quantification Software Analysis Tool (VevoCQ, VisualSonics, Canada), a region of 
interest (ROI) was defined around the bound MBs area (1 cm
2
). The mean contrast 
intensity within the ROI before and after the destructive pulse was evaluated, and 
each data point corresponded to the mean of the contrast intensity in the ROI in each 
frame. To highlight the contrast effect of targeted MBs, 50 frames after the destructive 
pulse were selected to create a reference baseline, and the frames before destructive 
pulse were overlaid to the reference baseline. The system isolated the targeted MBs 
echo from the tissue ultrasound signal data and identified them in green color. The 
process persistence filter was set to Smooth (to remove transient bubble data from the 
image), the contrast overlay dynamic range and threshold were used as default (50%). 
To analyze quantitatively the contrast enhancement effect, the mean values of contrast 
power of 200 frames before and after the destructive pulse were calculated by 
VevoCQ™ advanced contrast quantification software. The signal from the targeted 
MB was determined by subtracting the mean value after the destructive pulse from the 
one before. The obtained signal from the targeted MB was normalized to the value 
before the destructive pulse. 
Histological Evaluations: Rats were sacrificed with pentobarbital overdose 1 hour 
after injection of Fucoidan-RhoB-MBs. Inferior vena cave with thrombus was 
removed, washed in 0.9% NaCl, fixed in paraformaldehyde 4% (w/v), and then frozen. 
The vena samples were cryosectioned at 10 µm thickness and then stained with 
hematoxylin and eosin. The cell nuclei of a venous vascular wall were labeled with 
4’6-DiAmidino-2-PhenylIndole (DAPI) contained in mounting medium (Vecto 
laboratories), and Fucoidan-RhoB-MBs were visualized in red thanks to rhodamine B. 
Stained sections were observed by light/fluorescence microscopy using the NDPview 
software (Hamamatsu, Japan). The magnified images of the region of interest were 
used to show the position of microbubbles. 
Biodistribution of Fucoidan-RhoB-MBs was studied in a similar way. Briefly, 
liver, spleen, lungs, and kidneys were excised and washed at 1 h after injection of 
Fucoidan-RhoB-MBs. The samples were cryosectioned, cell nuclei were labeled with 
DAPI, and observed by fluorescence microscopy. 
Statistical Analysis: All results are presented as the mean ± standard deviation 
(SD). Statistical differences for multiple groups were determined using a one-way 
ANOVA, and each experiment was performed using Student’s t-test. Probabilities of p 
< 0.05 were considered significant. Statistical analyses were performed using 
GraphPad Prism 5.0. 
  
3. Results and Discussion 
3.1. Preparation and Characterization of Microbubbles 
Limitations of the first generation of MBs were addressed either by incorporating the 
echogenic reflective air component into less permeable coatings, such as organic 
polymers and cross-linked proteins, or by employing less soluble gaseous compounds 
[43]. Since the first PBCA MBs developed by Harris et al., several antibodies and 
peptides were employed to produce targeted PBCA MBs with a multi-step synthesis 
for molecular ultrasound imaging [44]. However, immunogenicity and cost of 
antibodies limited their use in humans. Moreover, the production of these targeted 
bubbles is also time-consuming due to their multi-step synthesis (carboxyl groups 
introduced on the surface through partial hydrolysis of the shell of PBCA MBs [45]). 
Furthermore, the degree of hydrolysis is difficult to control, and the excess of 
hydroxyl or redundant reaction time may induce rapid depolymerization reaction 
destroying the structure of MBs and producing short chains of PBCA [46]. 
 
Figure 1. Overall schematic diagram of one-step protocol for microbubbles and their use as 
molecular ultrasound contrast agent. 
In this work, we reported air-filled PIBCA MBs coated with various polysaccharides 
in a novel simple one-pot procedure (Figure 1). The size distribution of MBs before 
and after polysaccharide functionalization was not altered (Table 1), all MBs showing 
a single peak with a narrow size distribution (Figure S1 Left). The surface charge of 
MBs was similar to the charge of polysaccharides (Table 1 and Figure S1 Right), 
indicating that polysaccharides were present at the surface of the MBs [47, 48]. 
Among the polysaccharides, DEAE-Dextran and CM-Dextran could respectively 
provide amino groups and carboxyl groups on the surface of PIBCA MBs for further 
functionalization. 
 
 
 
 
 
 
 
 
Table 1. Characteristics of non-functionalized and polysaccharide functionalized microbubbles. 
Since CM-dextran had a similar negative surface charge but without the sulfate 
groups of fucoidan that are involved in its interaction with P-selectin, 
CM-Dextran-MBs were chosen as a control to assess the benefit of using targeted 
MBs (Fucoidan-MBs). Morphology images of CM-Dextran-MBs and Fucoidan-MBs 
obtained by electron microscopy showed that all MBs were spherical with an empty 
 Size distributions ζ  
(mV) D10 (μm) D50 (μm) D90 (μm) 
MBs 2.34 ± 0.01 3.69 ± 0.01 5.85 ± 0.01 -15.33 ± 0.40 
Dextran-MBs 2.46 ± 0.01 3.90 ± 0.02 6.18 ± 0.06 -8.56 ± 0.50 
DEAE-Dextran-MBs 2.63 ± 0.05 4.03 ± 0.10 6.06 ± 0.21 44.20 ± 2.38 
CM-Dextran-MBs 2.53 ± 0.02 4.03 ± 0.05 6.44 ± 0.14 -34.33 ± 0.47 
Fucoidan-MBs 2.40 ± 0.02 3.83 ± 0.03 6.23 ± 0.12 -42.80 ± 1.47 
core loaded with air (Figure 2 Left). Under Environmental Scanning Electron 
Microscopy (ESEM), low vacuum protected the integrity of MBs structure, and both 
MBs presented similar size by DLS measurement. Fluorophore-labeled MBs in 
combination with fluorescence microscopy were very powerful tools for clearly 
visualizing and validating in vitro and in vivo binding studies. However, the loading 
strategy should be carefully designed to avoid an alteration of the surface functional 
groups of MBs. Here, rhodamine-loaded Fucoidan-MBs (Fucoidan-RhoB-MBs) and 
CM-Dextran-MBs (CM-Dextran-RhoB-MBs) were prepared by modification of the 
synthesis methods of Liu. [49]. The loading of rhodamine into the MBs polymer 
membrane did not affect the size distribution and zeta potential of MBs. To 
demonstrate the presence of CM-Dextran or fucoidan on MBs, FITC-CM-Dextran or 
FITC-fucoidan was added, respectively (Figure S2). Size distribution and zeta 
potential of all the labeled MBs were presented in Table S1. The double-labeled MBs 
observed by confocal microscopy imaging confirmed the core-shell structure of MBs 
and the presence of polysaccharides on the shell (Figure 2 Right). 
 
Figure 2. Morphology characterizations of CM-Dextran-MBs and Fucoidan-MBs (Left) and 
fluorescently labeled microbubbles (Right). The green fluorescence signal is from 
FITC-CM-Dextran or FITC-Fucoidan, and the red fluorescence signal is from rhodamine (Scale 
bar for confocal images: 5 μm). 
The amount of fucoidan coupled to the MBs was quantified by a solid-phase 
colorimetric assay described by Lee. [41]. Based on the standard curves, we 
calculated the fucoidan content of Fucoidan-MBs to be of 8.6 × 10
-15
 g per 
Fucoidan-MB (Figure S3). 
As a potential contrast agent, the storage of MBs is very important. Long-term storage 
stability of the MBs in aqueous suspensions at 4
o
C was evaluated. Results showed 
that size and zeta potential remained stable for at least 2 months for both MBs (Figure 
3). 
 
Figure 3. Stability of size and zeta potential of CM-Dextran-MBs and Fucoidan-MBs kept at 4°C 
for 60 days (n=3). 
3.2 In vitro Flow Experiments 
Flow chamber experiments are used to mimic the interactions of MBs with purified 
P-Selectin or activated human platelets under physiological conditions in vitro [36, 
50]. After perfusion of human whole blood at high shear stress, activated DIOC6 
stained human platelets aggregated on collagen-coated chambers. Human platelet 
aggregates were visualized in real time under the fluorescent microscope (Video S1). 
P-selectin expression on activated platelets was evidenced by the green fluorescence 
uptake observed after injection of FITC-anti-CD62P antibody through the channel; no 
signal was detected after injection of FITC-IgG control (Figure S4). After perfusion 
at venous shear stress (6.75 dyn.cm
-2
) to mimic venous flow conditions of 
Fucoidan-RhoB-MBs (Video 1) or CM-Dextran-RhoB-MBs (Video S2) on preformed 
platelet aggregates, an uptake of red fluorescence was observed over time at the 
surface of the aggregates. After washing, bound Fucoidan-RhoB-MBs remained 
attached to the aggregates, whereas almost no remaining binding was observed with 
control CM-Dextran-RhoB-MBs (Figure 4A). Quantitative analysis confirmed that 
the mean fluorescent intensity (MFI) of fluorescent MBs was significantly higher for 
Fucoidan-RhoB-MBs than for CM-Dextran-RhoB-MBs (4387 ± 178.9 versus 1640 ± 
10.53, respectively, p<0.0001) (Figure 4B). To further confirm these results, 
CM-Dextran-RhoB-MBs and Fucoidan-RhoB-MBs were successively perfused into 
the same channel at constant shear stress, and the results showed clearly different 
targeting responses (Video S3). 
 Figure 4. Binding of microbubbles on activated platelet aggregates under flow conditions in vitro. 
A) Human whole blood labeled with 5 µM of DIOC6 (green) was first injected into channels 
coated with collagen to induce platelet aggregation (Left panels). Rhodamine labeled 
CM-Dextran-MBs or Fucoidan-MBs (red) were infused for 5 minutes onto activated platelet 
aggregates under venous flow conditions (6.75 dyn.cm
-2
). Channels were washed and observed by 
fluorescent microscopy (middle and right panels). B) Quantitative analysis of the mean fluorescent 
intensity (MFI) on platelet aggregates. One MFI value was obtained per channel on 20 platelet 
aggregates from 7 independent experiments (**** indicated p<0.0001). 
To confirm the binding of Fucoidan-MBs to activated platelets, we performed an ex 
vivo platelets-rich thrombus and added a suspension of Fucoidan-MBs for 5 minutes. 
After rinsing with saline, we observed the thrombus by Environmental Scanning 
Electron Microscopy. The ESEM images of the platelets-rich thrombus without MBs 
exhibited activated platelets and fibrin (Figure S5 Left). In contrast, the ESEM 
images of the platelets-rich thrombus in contact with Fucoidan-MBs showed many 
spherical micrometer particles (as Figure 2 Left) associated with the activated 
platelets confirming that Fucoidan-MBs bind to activated platelets overexpressing 
P-selectin. 
3.3. In vitro Ultrasound Imaging 
The potential of CM-Dextran-MBs and Fucoidan-MBs as contrast agents for 
ultrasound imaging was first assessed in vitro. A suspension of MBs (10
5
 mL
-1
) was 
put into the thin-wall tube and placed on the top of the probe (Figure 5A Left), and 
the echogenicity of MBs was evaluated by Vevo 2100. A Control suspension was used 
to check the background signal (Figure 5A Middle) which remained at low level 
(Figure 5A Right). For MBs suspensions, the imaging showed a high and stable 
enhancement of monodisperse contrast signal, which could be eliminated by 
destructive pulse (Figures 5B). Quantitative analysis proved that CM-Dextran-MBs 
and Fucoidan-MBs have similar contrast signals and both of them could be reduced to 
background level after burst (Figures 5C). These results indicated that the variation in 
echo after the burst could be used in vivo to ensure that the enhanced contrast signal 
was coming from MBs and not from motion artifact caused by respiratory and cardiac 
activities. 
 Figure 5. In vitro ultrasound signals of CM-Dextran-MBs and Fucoidan-MBs under B-mode. A) 
Image of the experimental set-up (Left); The control suspension of MBs shows the baseline signal 
(Middle); The B-mode mean power of 100 frames before and after high mechanical destructive 
pulse were calculated by VevoCQ™ and displayed by scatter plot (Right). B) Visualization of the 
contrast intensities before and after the burst to destroy CM-Dextran-MBs (Up) and 
Fucoidan-MBs (Down). C) Quantitative analysis of the B-mode mean power signals before and 
after the burst. (n=3; ns: non-significant; ***p<0.001). 
3.4. Cell Viability 
The cytotoxicity of Fucoidan-MBs was evaluated by MTT assay [51] with mouse 
fibroblast 3T3 cells exposed to various concentrations of Fucoidan-MBs or 
CM-Dextran-MBs. As shown in Figure S6, the results demonstrated that none of 
these MBs affected the cell viability (cell viability > 80% even at the highest 
concentrations of 10
7
 mL
-1
), suggesting an excellent in vitro safety of these MBs. 
Moreover, no significant difference was observed between CM-Dextran-MBs and 
Fucoidan-MBs. 
3.5. In vivo Ultrasound Imaging and Environmental Scanning Electron 
Microscopy 
To evaluate the in vivo targeting of Fucoidan-MBs to P-selectin overexpressed on 
thrombus, the ferric chloride (FeCl3) induced inferior vena cava (IVC) non-occlusive 
thrombus rat model was performed. The presence of non-occlusive thrombus was 
inspected by B-mode, and the venous blood flow around thrombi was confirmed by 
Color Doppler Flow Imaging (Figure S7). Ten minutes after the injection of 
Fucoidan-MBs, the presence of bound Fucoidan-MBs in the thrombus region was 
accurately validated (green color) (Video 2). The signal intensity of binding area in 
the thrombus was remarkably decreased after MBs burst by destructive pulse (Figure 
6B). In contrast, the rats injected with control CM-Dextran-MBs showed few MBs in 
the thrombus region (Video S4), and the signal intensity declined only slightly after 
the destructive pulse (Figure 6A). Subsequent quantifications of the decreased signal 
intensity in the thrombus area before and after destructive pulse evidenced a 
significantly higher accumulation of Fucoidan-MBs in comparison to 
CM-Dextran-MBs (85.5 ± 2.7% versus 50.8 ± 8.4%, respectively, p<0.0001) (Figure 
6C). Furthermore, no Fucoidan-MBs were detected in the inferior vein wall of healthy 
rats (Figure S8). In addition, the healthy rats used in these experiments were still alive 
a few months after injection of MBs and without any side effects. 
 Figure 6. The thrombus area ultrasound imaging of ferric-chloride-induced inferior vena cava 
thrombosis rat model was acquired and analyzed for 10 min after injection of MBs. 50 frames 
after the destructive pulse were selected as a reference, and the contrast signals that only exist in 
the frame before burst were highlighted by green color. The contrast mean power of 200 frames 
before and after high mechanical destructive pulse was calculated by VevoCQ™ and represented 
in scatter plot. The mean value of contrast mean power before and after the burst was used for the 
following quantitative analyses. A) After injection of CM-Dextran-MBs, few bound MBs were 
found in thrombus region. B) A significant microbubble-induced signal (green) was present in the 
thrombus area after injection of Fucoidan-MBs. C) Quantitative analysis of the signals before and 
after the burst. On the right panel, the contrast mean power after the burst was normalized to the 
one before the burst (5 rats for CM-Dextran-MBs and 5 rats for Fucoidan-MBs, ****p<0.0001). 
To confirm the presence of Fucoidan-MBs bound onto the thrombus, we visualized 
the opened inferior cava vena with thrombus by Environmental Scanning Electron 
Microscopy (ESEM). ESEM images proved that the thrombus rat model induced by 
ferric chloride (FeCl3) was non-occlusive (Figure 7 Left) and that there were many 
Fucoidan-MBs at the luminal surface of the thrombus targeting the P-selectin 
overexpressed (Figure 7 Right). 
 
Figure 7. Environmental Scanning Electron Microscopy (ESEM) images of a non-occlusive 
inferior vena cava thrombus rat model with Fucoidan-MBs bound at the luminal surface of the 
thrombus (Left). Magnification of a region of interest and white arrows highlight the 
Fucoidan-MBs (Right). Scale bars are 100 µm and 30 µm for the magnified area. 
Owing to the poor contrast, quantitative analysis of ultrasound signal modification has 
been a difficult issue in the field of ultrasound molecular imaging [42, 52, 53]. Unlike 
non-motile solid tumor, blood vessel walls are always dilated or contracted due to the 
heartbeat, adding to the difficulty of thrombi imaging analysis. Currently, the main 
ultrasound imaging methods of thrombus analysis are based on the contrast overlay 
data that is created by comparing the imaging before and after the injection of MBs 
[42, 52, 53]. This approach could potentially overcome the interference of motion 
artifacts, but it failed to distinguish the false increased contrast signal caused by the 
growth of thrombi. Herein, we exploited a differential imaging method to evaluate the 
targeting efficiency of MBs. Thanks to this method, we were able to distinctly see the 
binding site of MBs, quantify the number of targeted MBs, and also monitor the 
elimination of MBs. Previous studies have shown that the combination of MBs and 
ultrasound can help temporarily to open the blood-brain-barrier via sonoporation 
mechanisms, these phenomena can contribute to the delivery of pharmaceutical 
treatments [54-57]. Herein, we observed for the first time that Fucoidan-MBs which 
were localized in the thrombus could be destroyed by a destructive pulse. These 
results indicated that Fucoidan-MBs carrying thrombolytic drugs could be a 
promising delivery system to improve thrombolytic efficiency while reducing 
hemorrhagic complications via the local release of the drug-loaded Fucoidan-MBs at 
the pathological site. 
3.6. Tissue Distribution in Healthy and Thrombus-Induced Rats. 
To evaluate the biodistribution in healthy rats, the presence of Fucoidan-RhoB-MBs 
in four main organs of excretion (liver, spleen, lungs and kidneys) was assessed by 
histological analysis of several sections for each organ (Figure S9). Results revealed 
that few Fucoidan-RhoB-MBs were found in liver, lungs and kidneys (indicated by 
the arrows). Conversely, red fluorescence was detected in the spleen with irregular 
shapes probably due to the degradation of the microbubbles. Indeed, various 
degradation processes of PACA nanoparticles were described [58, 59]. One leading 
view was that the main products of biodegradation of PACA nanoparticles were 
polymer chains and the corresponding alcohol, which were formed after cleavage of 
ester bond by esterases [60-62]. This also confirmed that the red fluorescent fragments 
we observed possibly arise from enzymatic hydrolysis in the spleen. Considering the 
results of the absence of cell toxicity and the low injection doses of Fucoidan-MBs or 
CM-Dextran-MBs in vivo, these MBs seem to be safe. 
To assess whether Fucoidan-MBs accumulated in vivo within an inferior venous 
thrombus, histology was performed under bright field and fluorescent microscopes. 
Results confirmed that thrombus existed in the inferior deep vein (Figure 8A), 
smooth muscle cells from venous vascular wall labeled with DAPI showed blue color 
(Figure 8B), and many scattered Fucoidan-RhoB-MBs (indicated by the arrows) were 
localized in the thrombus area (Figures 8C & 8D). Few MBs showed 
microbubble-like shapes, most of them were altered and fractured (Figures 8C & 8D 
Right), likely due to high destructive pulse that destroyed their structure. 
 
 Figure 8. Histological analysis of thrombi in the IVC sections. Hematoxylin and Eosin staining (A) 
and DAPI staining (B). Red Fucoidan-RhoB-MBs were only observed in the thrombus area (C). 
Merge section of DAPI and Fucoidan-RhoB-MBs (D). Inserts are magnification of Regions of 
Interest (C & D Right). The region of thrombus is denoted with the yellow dotted line. 
  
4. Conclusion 
In this work, various polysaccharide-coated PIBCA MBs were developed according to 
a new easy one-step polymerization reaction. This method allowed convenient 
modulation of the different surface functional groups of MBs, which were prone to 
further functionalization. Among the polysaccharides, fucoidan was especially 
considered to functionalize the MBs due to its high affinity for P-selectin. Compared 
to anionic carboxymethylated dextran MBs, Fucoidan-MBs specifically bind to 
P-selectin expressed by human activated platelets at venous shear stress. An in vivo rat 
model showed that Fucoidan-MBs were able to target thrombus. We evidenced their 
presence in the thrombus by ultrasound imaging and histology analysis. This approach 
offers a sensitive and specific method to detect microthrombi before complete 
occlusion of the vessel using an inexpensive and widely used ultrasound equipment in 
hospitals and medical centers worldwide. Fucoidan-MBs application could also be 
extended to molecular monitoring of P-selectin expression in severe diseases. More 
in-depth studies of the in vivo performance of Fucoidan-MBs should be performed 
before moving towards clinical implementation. In addition, antithrombotic or 
fibrinolytic drugs could be incorporated into the Fucoidan-MBs, and these targeted 
MBs burst by ultrasound could locally deliver the drugs at the thrombus site, which 
represents a new promising theranostic system. 
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Video Legends 
Video 1: In vitro real time fluorescent images of Fucoidan-MBs infusion onto activated platelet 
aggregates in venous conditions. 
Video 2: In vivo real time ultrasound imaging before and after burst of Fucoidan-MBs on 
thrombus. 
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 Table S1. Characteristics of fluorescent polysaccharide functionalized microbubbles. 
  
 Size distributions ζ 
(mV) D10 (μm) D50 (μm) D90 (μm) 
CM-Dextran-RhoB-MBs 2.17 ± 0.01 3.49 ± 0.01 5.86 ± 0.02 -32.1 ± 0.5 
FITC-CM-Dextran-MBs 2.35 ± 0.01 3.69 ± 0.01 5.76 ± 0.05 -35.9 ± 0.9 
FITC-CM-Dextran-RhoB-MBs 2.21 ± 0.01 3.52 ± 0.01 5.65 ± 0.04 -32.8 ± 1.0 
Fucoidan-RhoB-MBs 2.16 ± 0.01 3.53 ± 0.01 6.14 ± 0.06 -41.6 ± 0.3 
FITC-Fucoidan-MBs 2.39 ± 0.02 3.74 ± 0.05 5.85 ± 0.13 -44.6 ± 0.7 
FITC-Fucoidan-RhoB-MBs 2.30 ± 0.01 3.67 ± 0.01 5.86 ± 0.02 -40.7 ± 0.8 
  
Figure S1. Size and zeta potential for several polysaccharide functionalized microbubbles. 
  
  
 
Figure S2. Flow cytometry evaluation of fluorescently labeled microbubbles. Unlabeled 
CM-Dextran-MBs and Fucoidan-MBs show grey color (PE & FITC negative). The green 
fluorescence signal (FITC positive) is associated to the FITC-CM-Dextran or FITC-Fucoidan, and 
the red fluorescence signal (PE positive) comes from rhodamine. Double labeled MBs show 
yellow color in the middle (PE & FITC positive). 
  
  
Figure S3. Quantification of fucoidan content in microbubbles. A) The spots of CM-Dextran and 
fucoidan at the reported concentrations were stained with methylene blue. B) The calibration curve 
obtained by optical density measurements (black dots and line) and the amount of fucoidan in 
Fucoidan-MBs (red dotted line). C) Spots obtained with hydrolysate solution of CM-Dextran-MBs 
or Fucoidan-MBs stained with methylene blue.  
  
Figure S4. Expression of P-selectin on activated platelet aggregates evidenced by FITC-labeled 
anti-P-selectin. Blood was perfused in collagen-coated micro-channels at arterial shear stress (67.5 
dyn.cm
-2
). Activation and aggregation of platelets were visualized by phase contrast microscopy 
(Left panels). FITC-labeled IgG with matched isotype (Up) or FITC-labeled anti-P-selectin 
(Down) was used to observe P-selectin expression on platelet aggregates (Middle panels; Right 
panels for Merged images). 
  
 Figure S5. Environmental Scanning Electron Microscopy (ESEM) image of an ex-vivo 
platelets-rich thrombus (Left). ESEM image of a platelets-rich thrombus in contact with 
Fucoidan-MBs (Right). White arrows highlight some Fucoidan-MBs. Scale bar = 30 µm for both 
images. 
  
 Figure S6. Cell viability determined by MTT assay of 3T3 cells after 24 hours exposure to 
different concentrations of CM-Dextran-MBs or Fucoidan-MBs (n=5). 
  
 Figure S7. A) Ultrasound imaging of inferior vena cava of healthy rat under B-mode (Up). Color 
Doppler flow imaging of the same region showed regular fluidity and low velocity (Down). B) 
Ultrasound imaging after the formation of the thrombus (Up); Color Doppler showed the region of 
blood flow, and Pulsed-wave indicates the irregular flow velocity (Down). 
  
Figure S8. Ultrasound imaging of the inferior vena cava of healthy rat was analyzed for 10 min 
after Fucoidan-MBs injection. The contrast means power values of 200 frames before and after the 
destructive pulse are shown.  
 Figure S9. Histological analysis of Fucoidan-RhoB-MBs in four organs. Nucleus cells appear in 
blue fluorescence, and MBs appear in red fluorescence. Few MBs are detected in the liver, lungs, 
and kidneys, whereas red fluorescent fragments were found in spleen (Scale bar: 50 μm). 
  
Video Legends 
Video S1: In vitro real time fluorescent images of activated platelets adhesion onto collagen. 
Video S2: In vitro real time fluorescent images of CM-Dextran-MBs infusion onto activated 
platelet aggregates in venous conditions. 
Video S3: CM-Dextran-MBs and Fucoidan-MBs were successively perfused into the same 
channel at venous shear stress. 
Video S4: In vivo real time ultrasound imaging before and after the burst of CM-Dextran-MBs on 
thrombus. 
 
